SCHEMBL4267530

SCHEMBL4267530

O=C1Oc2ccccc2C1=Cc1ccc(O)c(O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 3/20 0.76
▸ TOP2A P11388 1/20 0.76
▸ STK17B O94768 6/20 0.68
▸ MEN1 O00255 5/20 0.68
▸ KMT2A Q03164 5/20 0.68
▸ RECQL P46063 3/20 0.68
▸ AURKA O14965 2/20 0.68
▸ GSK3B P49841 2/20 0.68
▸ HDAC3 O15379 1/20 0.68
▸ HDAC4 P56524 1/20 0.68
▸ HDAC1 Q13547 1/20 0.68
▸ HDAC7 Q8WUI4 1/20 0.68
▸ HDAC2 Q92769 1/20 0.68
▸ HDAC10 Q969S8 1/20 0.68
▸ HDAC11 Q96DB2 1/20 0.68
▸ HDAC8 Q9BY41 1/20 0.68
▸ TDP1 Q9NUW8 1/20 0.68
▸ HDAC6 Q9UBN7 1/20 0.68
▸ HDAC9 Q9UKV0 1/20 0.68
▸ HDAC5 Q9UQL6 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267528 1.00 TOP1 (0.76) TOP1TOP2ASTK17BMEN1KMT2A
SCHEMBL4256999 0.85 TOP1 (1.00) TOP1TOP2ASTK17BMEN1KMT2A
SCHEMBL4257003 0.85 TOP1 (1.00) TOP1TOP2ASTK17BMEN1KMT2A
SCHEMBL4261091 0.81 TOP1 (0.75) TOP1TOP2ASTK17BMEN1KMT2A
SCHEMBL4261090 0.81 TOP1 (0.75) TOP1TOP2ASTK17BMEN1KMT2A
SCHEMBL29646271 0.81 STK17B (1.00) STK17BMEN1KMT2ARECQLAURKA
SCHEMBL3709615 0.81 STK17B (1.00) STK17BMEN1KMT2ARECQLAURKA
SCHEMBL3709614 0.81 STK17B (1.00) STK17BMEN1KMT2ARECQLAURKA
SCHEMBL28720187 0.79 LCK (1.00) TOP1STK17BMEN1KMT2ARECQL
SCHEMBL29516754 0.79 LCK (1.00) TOP1STK17BMEN1KMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629375-B2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2009-12-08 — — US disclosed
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2006-08-10 — — US disclosed
EP-1435894-A4 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO PHARMACEUTICALS INC (US) 2005-07-06 — — EP disclosed
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER INC. 2005-06-30 — — US disclosed
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods GALILEO PHARMACEUTICALS, INC. 2005-05-26 — — US disclosed
EP-1435894-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS Galileo Pharmaceuticals, Inc. (US) 2004-07-14 — — EP disclosed
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-17 — — US disclosed
WO-2003009807-A2 CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS GALILEO LABORATORIES, INC. (US) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142155-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 TOP1 1758/4885TOP2A 1419/4885STK17B 2724/4885
US-20030073712-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 TOP1 1758/4885TOP2A 1419/4885STK17B 2724/4885
US-20050113416-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 TOP1 1758/4885TOP2A 1419/4885STK17B 2724/4885
US-20060178356-A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods HSF1, HMOX1, NQO1 TOP1 1758/4885TOP2A 1419/4885STK17B 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback